Literature DB >> 2221963

Slow release carbamazepine in treatment of poorly controlled seizures.

S W Ryan1, I Forsythe, R Hartley, M Haworth, C J Bowmer.   

Abstract

Thirty three children with poorly controlled epilepsy, and six new patients, were treated with slow release carbamazepine. Twelve of the former had a reduction in the number of seizures of more than half, and 10 had fewer side effects. Three of the new patients stopped having seizures. Variations in plasma concentrations between doses was significantly less when patients took the slow release preparation (22%) compared with the standard preparation (41%). Slow release carbamazepine may improve the conditions of children whose seizures are poorly controlled.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2221963      PMCID: PMC1792095          DOI: 10.1136/adc.65.9.930

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  14 in total

1.  A comparison of carbamazepine divitabs with carbamazepine normal formulation in psychiatric and oligophrenic patients. Preliminary pharmacokinetic results.

Authors:  A J Loonen; P J Toll; J R Nijdam
Journal:  Pharm Weekbl Sci       Date:  1989-02-24

2.  Carbamazepine as an anticonvulsant: a pilot study.

Authors:  A S Troupin; J R Green; R H Levy
Journal:  Neurology       Date:  1974-09       Impact factor: 9.910

3.  Reduction of dosing frequency of carbamazepine with a slow-release preparation.

Authors:  J Sivenius; E Heinonen; H Lehto; P Järvensivu; M Anttila; A Ylinen; P Riekkinen
Journal:  Epilepsy Res       Date:  1988 Jan-Feb       Impact factor: 3.045

4.  Bioavailability and central side effects of different carbamazepine tablets.

Authors:  P J Neuvonen
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1985-04

5.  Correlation between daily fluctuations of carbamazepine serum levels and intermittent side effects.

Authors:  R J Höppener; A Kuyer; J W Meijer; J Hulsman
Journal:  Epilepsia       Date:  1980-08       Impact factor: 5.864

6.  Interdosage fluctuations in plasma carbamazepine concentration determine intermittent side effects.

Authors:  T Tomson
Journal:  Arch Neurol       Date:  1984-08

7.  Controlled release carbamazepine: cognitive side effects in patients with epilepsy.

Authors:  A P Aldenkamp; W C Alpherts; M C Moerland; N Ottevanger; J A Van Parys
Journal:  Epilepsia       Date:  1987 Sep-Oct       Impact factor: 5.864

8.  Carbamazepine plasma concentration. Relationship to cognitive impairment.

Authors:  M O'Dougherty; F S Wright; S Cox; P Walson
Journal:  Arch Neurol       Date:  1987-08

9.  Clinical monitoring during carbamazepine slow-release, once-daily monotherapy.

Authors:  H Stefan; H Schäfer; C Kuhnen; S Schneider
Journal:  Epilepsia       Date:  1988 Sep-Oct       Impact factor: 5.864

10.  A double-blind comparison of conventional and controlled-release carbamazepine in healthy subjects.

Authors:  J G Larkin; A McLellan; A Munday; M Sutherland; E Butler; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1989-03       Impact factor: 4.335

View more
  6 in total

Review 1.  Types of psychiatric treatment. Drug treatment.

Authors:  M Prendergast
Journal:  Arch Dis Child       Date:  1992-12       Impact factor: 3.791

Review 2.  Pharmacokinetics and Pharmacogenetics of Carbamazepine in Children.

Authors:  Natasa Djordjevic; Slobodan M Jankovic; Jasmina R Milovanovic
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-10       Impact factor: 2.441

Review 3.  Pharmacokinetic evaluation of sustained release formulations of antiepileptic drugs. Clinical implications.

Authors:  M Bialer
Journal:  Clin Pharmacokinet       Date:  1992-01       Impact factor: 6.447

4.  Double dummy comparison between once and twice daily dosing with modified-release carbamazepine in epileptic patients.

Authors:  P J McKee; J Blacklaw; A Carswell; R A Gillham; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1993-09       Impact factor: 4.335

5.  Childhood Epilepsy : Current Therapeutic Recommendations.

Authors:  J T Gilman; M Duchowny
Journal:  CNS Drugs       Date:  1994-03       Impact factor: 5.749

Review 6.  Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate.

Authors:  D Battino; M Estienne; G Avanzini
Journal:  Clin Pharmacokinet       Date:  1995-11       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.